| Contributors |
|
ix | |
|
|
|
1 | (4) |
|
1.1 Early development of bioresorbable scaffold |
|
|
2 | (3) |
|
|
|
|
|
|
|
PART 2 PRINCIPLES OF BIORESORPTION, VASCULAR APPLICATION |
|
|
5 | (38) |
|
2.1 Degradable, biodegradable, and bioresorbable polymers for time-limited therapy |
|
|
6 | (9) |
|
|
|
2.2 Lactic acid-based polymers in depth |
|
|
15 | (7) |
|
|
|
|
|
|
|
22 | (7) |
|
|
|
|
|
|
|
|
|
2.4 Basics of magnesium biodegradation |
|
|
29 | (9) |
|
|
|
|
|
|
|
|
|
2.5 Basics of biodegradation of iron scaffold |
|
|
38 | (5) |
|
|
|
|
|
PART 3 FROM BENCH TEST TO PRECLINICAL ASSESSMENT |
|
|
43 | (52) |
|
3.1 Unlocking scaffold mechanical properties |
|
|
44 | (9) |
|
|
|
|
|
|
|
|
|
3.2 Bench testing for polymeric bioresorbable scaffolds |
|
|
53 | (7) |
|
|
|
|
|
|
|
|
|
|
|
|
|
3.3 Bench test for magnesium scaffold |
|
|
60 | (8) |
|
|
|
|
|
|
|
|
|
|
|
|
|
3.4 Simulation of flow and shear stress |
|
|
68 | (13) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3.5 Preclinical assessment of bioresorbable scaffolds and regulatory implication |
|
|
81 | (14) |
|
|
|
|
|
|
|
|
|
PART 4 LESSONS LEARNED FROM PRECLINICAL ASSESSMENT |
|
|
95 | (28) |
|
|
|
96 | (21) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
117 | (6) |
|
|
|
|
|
|
|
|
|
|
|
|
|
PART 5 IMAGING TO EVALUATE THE BIORESORBABLE SCAFFOLD: A core lab perspective: Methodology of measurement and assessment |
|
|
123 | (82) |
|
5.1 Quantitative coronary angiography of bioresorbable vascular scaffold: A core lab perspective |
|
|
124 | (10) |
|
|
|
|
|
|
|
5.2 Assessment of bioresorbable scaffolds by IVUS: Echogenicity, virtual histology, palpography |
|
|
134 | (8) |
|
|
|
|
|
5.3 Optical coherence tomography analysis of bioresorbable vascular scaffold in comparison with metallic stents: A core lab perspective |
|
|
142 | (18) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5.4 Noninvasive coronary computed tomography analysis after bioresorbable scaffold implantation |
|
|
160 | (5) |
|
|
|
|
|
|
|
|
|
5.5 Angiography is sufficient |
|
|
165 | (4) |
|
|
|
|
|
5.6 Intravascular ultrasound is a must in bioresorbable scaffold implantation |
|
|
169 | (8) |
|
|
|
|
|
|
|
|
|
177 | (11) |
|
|
|
Nienke Simone van Ditzhuijzen |
|
|
|
|
|
|
|
|
|
|
|
|
5.8 Imaging to evaluate the bioresorbable scaffold---Clinicians' perspective: I need both (IVUS and OCT) |
|
|
188 | (6) |
|
|
|
|
|
5.9 Multislice computed tomography as a modality of follow-up |
|
|
194 | (11) |
|
|
|
|
|
|
|
|
|
PART 6 CLINICAL EVIDENCE OF RANDOMIZED AND NONRANDOMIZED TRIALS: Personal perspective |
|
|
205 | (120) |
|
6.1 What are appropriate clinical endpoints? From device failure assessment to angina evaluation |
|
|
207 | (8) |
|
|
|
|
|
|
|
6.2 Angina reduction after BRSs implantation: Correlation with changes in coronary hemodynamics |
|
|
215 | (9) |
|
|
|
|
|
|
|
6.3 Comparison of everolimus-eluting bioresorbable scaffolds with everolimus-eluting metallic stents for treatment of coronary artery stenosis: Three-year follow-up of the ABSORB II randomized trial |
|
|
224 | (14) |
|
|
|
|
|
|
|
Angel Ramon Cequier Fillat |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6.4 The ABSORB China trial |
|
|
238 | (5) |
|
Runlin Gao on behalf of the ABSORB China Investigators |
|
|
|
|
243 | (11) |
|
|
|
6.6 What have we learned from meta-analysis of 1-year outcomes with the ABSORB bioresorbable scaffold in patients with coronary artery disease? |
|
|
254 | (9) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6.7 Summary of investigator-driven registries on ABSORB bioresorbable vascular scaffolds |
|
|
263 | (9) |
|
|
|
|
|
|
|
6.8 Investigator-driven randomized trials |
|
|
272 | (11) |
|
|
|
|
|
|
|
|
|
283 | (11) |
|
|
|
|
|
|
|
|
|
6.10 Results of clinical trials with BIOTRONIK magnesium scaffolds |
|
|
294 | (11) |
|
|
|
|
|
|
|
|
|
|
|
6.11 The REVA Medical Program: From ReZolve® to Fantom® |
|
|
305 | (4) |
|
|
|
|
|
6.12 The Amaranth bioresorbable vascular scaffold technology |
|
|
309 | (7) |
|
|
|
|
|
|
|
6.13 The Mirage microfiber sirolimus eluting coronary scaffold |
|
|
316 | (3) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
6.14 The Igaki--Tamai stent: The legacy of the work of Hideo Tamai |
|
|
319 | (6) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PART 7 CLINICAL EVIDENCE IN SPECIFIC PATIENT SUBSETS: Personal perspective |
|
|
325 | (86) |
|
7.1 Left main interventions with BRSs |
|
|
326 | (6) |
|
|
|
|
|
|
|
|
|
|
|
7.2 Bioresorbable scaffolds in bifurcations |
|
|
332 | (8) |
|
|
|
|
|
|
|
7.3 BVSs in chronic total occlusions: Clinical evidence, tips, tricks |
|
|
340 | (7) |
|
|
|
7.4 Bioresorbable scaffolds in diffuse disease |
|
|
347 | (7) |
|
|
|
|
|
|
|
7.5 Bioresorbable scaffolds in multivessel coronary disease |
|
|
354 | (8) |
|
|
|
|
|
|
|
7.6 Bioresorbable coronary scaffolds in non-ST elevation acute coronary syndromes |
|
|
362 | (7) |
|
|
|
|
|
7.7 Bioresorbable vascular scaffold in ST-segment elevation myocardial infarction: Clinical evidence, tips, tricks |
|
|
369 | (10) |
|
|
|
|
|
7.8 Bioresorbable scaffolds for treating coronary artery disease in patients with diabetes mellitus |
|
|
379 | (10) |
|
|
|
|
|
|
|
7.9 BRSs in calcified lesions |
|
|
389 | (9) |
|
|
|
|
|
7.10 Invasive sealing of vulnerable, high-risk lesions |
|
|
398 | (13) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PART 8 COMPLICATIONS (INCIDENCE, DIAGNOSIS, POTENTIAL MECHANISMS AND TREATMENT) |
|
|
411 | (58) |
|
8.1 Acute and subacute scaffold thrombosis |
|
|
412 | (9) |
|
|
|
8.2 Late and very late scaffold thrombosis |
|
|
421 | (10) |
|
|
|
|
|
|
|
|
|
|
|
|
|
8.3 Treatment of bioresorbable scaffold failure |
|
|
431 | (8) |
|
|
|
|
|
|
|
|
|
|
|
8.4 Recoil and bioresorbable scaffolds |
|
|
439 | (5) |
|
|
|
|
|
|
|
|
|
8.5 Acute scaffold disruption and late discontinuities |
|
|
444 | (18) |
|
|
|
|
|
|
|
|
|
|
|
8.6 The incidence and potential mechanism of side-branch occlusion after implantation of bioresorbable scaffolds: Insights from ABSORB II |
|
|
462 | (7) |
|
|
|
|
|
|
|
|
|
|
|
PART 9 TIPS AND TRICKS TO IMPLANT BRSs |
|
|
469 | (14) |
|
9.1 Tips and tricks for implanting BRSs: Sizing, pre- and postdilatation |
|
|
470 | (7) |
|
|
|
|
|
|
|
9.2 Approach to bifurcation lesions |
|
|
477 | (6) |
|
|
|
|
|
PART 10 EMERGING TECHNOLOGIES (PRE-CE MARK, PRE-FA, PRE-PMDA, PRE-CFDA) |
|
|
483 | (30) |
|
10.1 Abbott: Current and next generation ABSORB scaffold |
|
|
484 | (7) |
|
|
|
|
|
|
|
10.2 Emerging technologies: Overview of the field |
|
|
491 | (3) |
|
|
|
|
|
|
|
|
|
10.3 MeRes100™---A sirolimus eluting bioresorbable vascular scaffold system |
|
|
494 | (6) |
|
|
|
|
|
|
|
|
|
10.4 XINSORB bioresorbable vascular scaffold |
|
|
500 | (2) |
|
|
|
|
|
10.5 NeoVas™ bioresorbable coronary scaffold system |
|
|
502 | (1) |
|
|
|
|
|
10.6 ArterioSorb™ bioresorbable scaffold by Arterius Ltd. |
|
|
503 | (6) |
|
|
|
10.7 IBS™ bioresorbable scaffold by Lifetech |
|
|
509 | (4) |
|
|
|
|
|
|
| Index |
|
513 | |
